New Mexico Grants for Nonprofits

The Growing Convergence Research (GCR) initiative by the National Science Foundation (NSF) promotes innovative solutions to complex societal and scientific challenges through multidisciplinary collaboration. By integrating diverse expertise, GCR aims to address specific problems and foster new research paradigms. Proposals must outline a five-year plan, divided into two phases, with budgets not exceeding $1.2 million for Phase I and $2.4 million for Phase II. Successful projects are expected to lead to transformative advances in science and technology.

The Amazon Literary Partnership Grant supports nonprofit organizations in the U.S. that empower diverse and marginalized writers. Since 2009, it has provided over $17 million to various literary groups, fostering emerging talent across genres. Eligible organizations must focus on developing writers, celebrating storytelling, and connecting them with audiences. By funding innovative initiatives, Amazon helps ensure that underrepresented voices are heard in the literary community, contributing to a rich and diverse narrative landscape.

The CURE Childhood Cancer: Translation to CURE (T2C) award provides funding for groundbreaking research to improve outcomes for children with cancer. Offering up to $150,000 per year for two years, this grant supports innovative projects led by full-time faculty at nonprofit institutions. The initiative seeks to foster collaboration among researchers at all career stages, ensuring that promising ideas can take root and flourish, ultimately driving advancements in pediatric oncology.

The CURE Childhood Cancer Early Investigator Award supports emerging scientists in the fight against pediatric cancer. This grant offers up to $150,000 per year for two years, totaling $330,000. It is designed for early-career researchers at US-based nonprofit institutions, particularly those at the Instructor or Assistant Professor level. The award aims to foster innovative research that can lead to effective treatments for childhood cancer, emphasizing the importance of collaboration and scientific advancement.

The Sidney R. Baer, Jr. Foundation focuses on improving the lives of individuals with schizophrenia and bipolar disorder through education grants. By funding programs that enhance educational opportunities, the foundation aims to reduce isolation and promote understanding. Grants are awarded to qualified organizations that prioritize mental health initiatives, ensuring that those affected have access to the resources and support necessary for a better quality of life. The foundation's mission is rooted in the belief that education can be transformative for those facing mental health challenges.

The Sidney R. Baer, Jr. Foundation offers Criminal Justice Grants aimed at improving the lives of individuals with serious mental illnesses, particularly schizophrenia and bipolar disorder. With an emphasis on effective programs and support services, the foundation seeks to address the challenges faced by mentally ill individuals in the criminal justice system. The foundation prioritizes organizations that demonstrate a commitment to making a meaningful impact and improving the quality of life for those affected by these conditions.

The Sidney R. Baer, Jr. Foundation offers Reintegration Grants aimed at supporting individuals with schizophrenia and bipolar disorder. By focusing on abilities rather than symptoms, the foundation promotes recovery through various programs. Their funding helps organizations that maintain a commitment to mental health, ensuring that recipients receive necessary support, such as scholarships and facility management, to enhance their quality of life. The foundation believes in empowering individuals to actively participate in their recovery journey.

The Sidney R. Baer, Jr. Foundation offers Social Support Grants aimed at improving the lives of individuals living with schizophrenia and bipolar disorder. These grants focus on reducing stigma through education and advocacy, fostering a compassionate environment. The foundation prioritizes organizations that provide tangible support and resources, ensuring a meaningful impact on mental health. By addressing the challenges faced by those with mental illness, the foundation strives to create a more inclusive society that recognizes and supports their needs.

The Sidney R. Baer, Jr. Foundation offers Clinical Research Grants to support advancements in the treatment and understanding of schizophrenia and bipolar disorder. Focused on organizations with IRS tax-exempt status, these grants aim to enhance mental health services and research. By funding initiatives in cognitive and behavioral sciences, the foundation seeks to improve the lives of those affected by serious mental illness, ensuring they receive the support and resources necessary for a better quality of life.

The Melanoma Career Development Award (CDA) is offered by the Melanoma Research Foundation to support researchers dedicated to melanoma and its prevention. This award is designed for postdoctoral fellows with under five years of experience, research associates, scientists, staff scientists, assistant professors, and those focusing on melanoma prevention. The initiative promotes innovative research to advance understanding and treatment of melanoma, ultimately aiming to reduce its impact.

The Cooperative Education Fund, managed by the Cooperative Development Foundation, offers grants, scholarships, and sponsorships to support cooperative education initiatives. Annually, it allocates between $100,000 and $140,000, providing 10-15 grants ranging from $1,000 to $10,000. Eligible applicants include cooperatives and related organizations within the U.S. The Fund prioritizes research, educational material development, and sponsorship for educational events, ensuring resources remain accessible and non-proprietary.

The Cooperative Development Fund Grant supports cooperative development, research, and technical assistance for cooperatives focused on seniors, international development, and affordable housing. Grants, typically ranging from $20,000 to $30,000, are awarded once a year, with a two-stage application process: a concept paper followed by a full proposal for selected applicants. Up to two grants are awarded annually, with decisions announced shortly after the Advisory Board meeting in January.

The Spark Good: Strengthening Community Local Grants program by the Wal-Mart Foundation empowers local organizations through grants ranging from $250 to $5000. This initiative aims to enhance community welfare by supporting diverse projects, including animal shelters and educational programs. Eligible organizations must have a verified Spark Good account, ensuring funds are allocated effectively to meet local needs and foster community development. Together, we can create lasting impacts through small yet significant actions.

The Therapeutic Giving program by Johnson & Johnson Innovative Medicine focuses on supporting nonprofit organizations that enhance patient access to treatment in cardiovascular and metabolic health. Applications are encouraged for initiatives that promote education, empower patients, and address healthcare disparities. Eligible organizations must be IRS 501(c)(3) certified, with a preference for programs demonstrating measurable outcomes. The funding period for local organizations extends from January to October 15th, while national organizations can apply in September.

The Therapeutic Giving program by Johnson & Johnson Innovative Medicine focuses on enhancing patient access to treatment in cardiovascular and metabolism areas. Nonprofit organizations classified as 501(c)(3) are eligible to apply for funding. The program emphasizes innovative initiatives that address healthcare disparities and improve patient outcomes through education, advocacy, and support services. Applications are evaluated based on design, capacity, and potential impact, with a preference for programs over event-based funding.

The Therapeutic Giving program by Johnson & Johnson focuses on funding initiatives that enhance patient access to treatment and advance health equity, particularly in immunology. Eligible nonprofit organizations can apply for support aimed at improving health outcomes through innovative programs. The initiative prioritizes measurable impacts over fundraising activities, emphasizing the importance of addressing healthcare disparities and promoting disease awareness efforts for diseases like rheumatoid arthritis and psoriasis.

The Therapeutic Giving: Oncology program by Johnson & Johnson focuses on funding initiatives that enhance patient access to treatments and services, promote health equity, and strengthen healthcare workforces. It supports programs that raise disease awareness, empower patients, and improve health systems with measurable outcomes. Eligible applicants include nonprofit organizations with 501(c)(3) status, emphasizing innovative programs addressing healthcare disparities and unmet needs.

The Therapeutic Giving program from Johnson & Johnson Innovative Medicine aims to support local and regional organizations focused on improving patient access to treatment and advancing health equity. Eligible applicants include 501(c)(3) nonprofit organizations, with funding preferences for programs that address significant healthcare disparities, mental health initiatives, and innovative solutions with measurable outcomes. The application period for local organizations runs from March 1 to May 31, while national organizations can apply in September.

The Therapeutic Giving initiative by Johnson & Johnson focuses on funding programs in neuroscience aimed at enhancing patient access to treatments and promoting health equity. Nonprofit organizations classified as 501(c)(3) can apply for support from March 1 to May 31. The initiative emphasizes innovative, measurable programs in areas like Alzheimer’s disease and mental health, prioritizing those that address healthcare disparities and improve quality of life for affected individuals.

The NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33) invites applications for early phase clinical trials focused on natural products. This funding opportunity supports research into botanicals and dietary supplements that show promise based on preliminary evidence. Successful trials can receive up to six years of funding to enhance understanding of pharmacokinetics and clinical impacts. Applications must aim to optimize product delivery and explore innovative combinations with other treatment approaches.

The NCCIH Natural Product Early Phase Clinical Trial Award (R33) invites applications for early phase clinical trials of natural products like botanicals and dietary supplements. This funding aims to support studies that assess the impact of these products on target engagement and clinical outcomes. The NOFO encourages innovative designs that optimize delivery methods and investigate combinations with existing treatments. With a maximum support period of three years, the initiative seeks to translate basic science findings into practical clinical applications.

The NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required) invites applications for clinical trials focused on natural products, such as botanicals and dietary supplements. Emphasizing scientific validity, the program seeks to evaluate optimal dosages and patient responses in a hypothesis-driven manner. Applications must include substantial preliminary data to assess bioavailability and confirm measurable impacts on target engagement. Key deadlines range from March 2024 to October 2026, ensuring timely submissions for interested researchers.

The External Collaborative Research (ECR) program by Boehringer Ingelheim invites academic and community scientists to propose collaborative studies aimed at protocol development and result publication. This program offers potential drug and financial support, excluding direct salary for the Principal Investigator. Budgets must represent fair market value and will be negotiated further. Research interests span therapeutic areas including Cardio-Renal-Metabolic, Mental Health, Dermatology, and Oncology, encouraging innovative solutions to unmet medical needs.

The National MS Society's Clinician Scientist Development Awards aim to cultivate promising young investigators in multiple sclerosis research. This program supports postdoctoral fellows with three years of comprehensive training in academic medicine focused on MS. Applicants must hold a clinical degree and be licensed in the U.S. The Society prioritizes research that aligns with its Pathways to Cures Roadmap, which emphasizes stopping disease progression, restoring function, and preventing MS.

The National MS Society offers Harry Weaver Scholar Awards to support emerging researchers in multiple sclerosis. This prestigious award honors Dr. Harry Weaver's legacy and aims to facilitate independent research careers. Eligible candidates must have a doctoral degree and relevant postdoctoral training. The funding is designed to provide salary and grant support for five years, allowing awardees to establish competence in their research area. Applications should align with the Society's Pathways to Cures Roadmap.

The National Multiple Sclerosis Society offers a Medical Student Mentorship Program that provides a four-week clinical experience for medical students who have completed at least one year of school. This program aims to raise awareness about the challenges faced by individuals with MS and generate interest in careers focused on MS care. Students gain hands-on experience under the guidance of MS specialists, enhancing their understanding of the disease and its management.

The National Multiple Sclerosis Society offers the Sylvia Lawry Physician Fellowships to support MDs in acquiring essential clinical trial training. This fellowship aims to enhance expertise in conducting complex trials for MS therapies, fostering skills in protocol design, patient recruitment, and data analysis. Applicants must have relevant medical training and be engaged in ongoing MS clinical research. The program is vital for addressing the increasing demand for trained professionals in MS clinical trials, contributing to advancements in treatment.